Diligence memo · auto-generated · as of July 2, 2026
Organovo Holdings, Inc.
Organovo Holdings, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Organovo Holdings, Inc. operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Organovo Holdings, Inc. has raised $24M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.3M on 2012-02-08.
Most recent recorded round closed around 2012-12-21.
Valuation (modeled)modeled
Provath models Organovo Holdings, Inc. at approximately $277M (range $8.4M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.38× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era. Within the normal band (138% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 258 months.
Last raise 13.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 71% of Biotechnology peers (4293 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.